Physician profile
Benjamin W Goh
NPI 1821013459
$10,993.29
in general payments reported to CMS, 2019-2025
65 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $2,785 · 2021: $2,824 · 2022: $1,916 · 2023: $262 · 2024: $431 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $863.61 | 2019-2025 | Airsupra |
| Amgen INC. | $782.05 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $760.07 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.14 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $600.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $579.21 | 2019-2024 | |
| Pfizer INC. | $485.23 | 2019-2025 | |
| Astellas Pharma US INC | $431.27 | 2019-2022 | |
| Lilly USA, LLC | $391.11 | 2019-2025 | Kisunla |
| Allergan, INC. | $345.08 | 2019-2020 | |
| Glaxosmithkline, LLC. | $314.26 | 2020-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $284.73 | 2019-2022 | |
| Abbott Laboratories | $221.05 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Antares Pharma, INC. | $186.84 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Goh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.